全球神經再生療法市場

預計到 2030 年全球神經再生療法市場規模將達到 472 億美元

全球神經再生療法市場規模在 2024 年估計為 378 億美元，預計到 2030 年將達到 472 億美元，在 2024-2030 年分析期內的複合年成長率為 3.8%。 N-甲基-D-天門冬胺酸受體拮抗劑是報告中分析的細分市場之一，預計複合年成長率為 4.0%，到分析期結束時將達到 179 億美元。在分析期內，膽鹼酯酶抑制劑部分預計將以 2.8% 的複合年成長率成長。

美國市場規模估計為 103 億美元，中國市場預計複合年成長率為 7.0%

預計2024年美國神經再生治療市場規模將達103億美元。作為世界第二大經濟體的中國，預計2030年市場規模將達到95億美元，在2024-2030年分析期間的複合年成長率為7.0%。其他值得注意的區域市場包括日本和加拿大，預計在分析期間的複合年成長率分別為 1.5% 和 2.9%。在歐洲，德國的複合年成長率預計為 2.2%。

全球神經再生療法市場—主要趨勢與促進因素摘要

為什麼神經再生療法在治療中樞神經系統和周邊神經系統損傷方面在全球範圍內越來越受到青睞？

神經再生治療已成為神經科學和再生醫學的前沿領域，為中樞和周圍神經系統損傷患者帶來了希望。創傷、中風、神經退化性疾病和去髓鞘化等造成的神經損傷傳統上被認為是不可逆的，現在正成為介入治療的目標，以促進軸突再生、突觸重建、髓鞘再生和功能恢復。這種從症狀治療到實際神經組織修復的模式轉移正在徹底改變神經康復，並將神經再生定位為神經治療未來基石。

全球範圍內脊髓損傷、多發性硬化症、帕金森氏症、阿茲海默症和創傷性腦損傷發病率的不斷上升推動了對神經再生療法的需求。由於人口老化以及道路交通事故和運動傷害的增加，患有衰弱性神經病變的人數不斷增加。傳統治療方法只能提供有限的康復機會，並且主要側重於減緩疾病的進展。相較之下，神經再生療法旨在恢復失去的功能，從而產生了新一代的治療策略，這些策略是治癒性的而不是緩解性的。

幹細胞、生長因子和基因療法等新治療方法將如何改變神經再生？

神經再生療法的技術核心圍繞著尖端生技藥品和工程細胞系統。幹細胞療法，特別是間質幹細胞（MSC）、誘導性多功能幹細胞（iPSC）和神經前驅細胞，是臨床開發中最前線的方法之一。這些細胞分泌神經營養因子，調節炎症，並分化為有助於修復受損神經組織的神經元樣細胞。臨床試驗正在研究其在脊髓損傷、中風復健、肌萎縮側索硬化症、多發性硬化症等領域的應用，早期結果令人鼓舞。

生長因子療法，包括腦源性神經營養因子 (BDNF)、神經膠質細胞株源性神經營養因子 (GDNF) 和睫狀神經營養因子 (CNTF)，已透過病毒載體、生醫材料或直接注射進行給藥，以促進神經元存活和可塑性。針對神經發炎、髓鞘修復和突觸功能障礙的基因療法已顯示出良好的前景，尤其是在遺傳性神經退化性疾病。生醫材料支架、水凝膠基質和神經介面的進步也使得在局部和永續地輸送這些再生劑成為可能。這些技術進步正在重新定義治療預期，強調神經恢復和電路重新整合，而不是簡單的症狀抑制。

哪些臨床應用與病患群體正在塑造神經再生市場格局？

神經再生療法正在廣泛的臨床應用中進行研究，包括脊髓損傷、創傷性腦損傷 (TBI)、周邊神經損傷、缺血性中風、多發性硬化症以及 ALS 和帕金森氏症等神經退化性疾病。患有慢性神經損傷的患者，尤其是那些具有部分殘留功能或處於退化早期階段的患者，是目前再生療法的最佳候選人。小兒神經病學，特別是腦性麻痹和神經管缺陷，也是未來治療創新的目標。

北美、歐洲和亞太等神經創傷、中風和老齡化相關性神經退化發生率較高的地區正在推動臨床試驗活動和市場需求。美國在監管發展和幹細胞臨床基礎設施方面處於領先地位，而日本和韓國正在有利的管理體制下推動再生醫學臨床試驗。拉丁美洲和中東的新興市場正在投資發展康復基礎設施並參與國際臨床試驗，以便更廣泛地獲得實驗性再生療法。患者對參與臨床試驗的計劃和興趣的增加進一步擴大了市場基礎。

什麼將推動神經再生療法市場的長期成長和創新？

神經再生療法市場的成長受到幹細胞生物學、生物材料科學、分子神經生物學和精準基因編輯的融合所推動。對神經系統可塑性和刺激內源性修復機制的能力的認知正在改變神經損傷的臨床治療方法。先進治療藥物（ATMP）的法規結構正在完善，以加速再生神經療法的開發和商業化。公共和私人對神經再生研究的投資正在成長，跨學科合作正在刺激創新。

臨床檢驗、可擴展製造、道德採購和長期安全監測仍然是重大挑戰。然而，隨著早期試驗數據的成熟和交付技術的日益複雜，預計將有越來越多的神經再生產品獲得市場核准。數位神經復健工具、穿戴式神經刺激設備和遠端患者監護系統的整合度提高將進一步加強對治療依從性和結果的追蹤。隨著神經再生成為神經治療的重要支柱，它很可能在恢復全球數百萬人的功能和改善他們的生活品質方面發揮變革性的作用。

部分

藥物類型（N-甲基-D-天冬胺酸受體拮抗劑、膽鹼酯酶抑制劑、多巴胺促效劑、免疫調節劑、其他藥物類型）、適應症類型（帕金森氏症適應症、阿茲海默症適應症、多發性硬化症適應症、其他適應症）、給藥途徑（口服途徑、腸外途徑、經皮症適應症、多發性硬化症適應症、其他適應症）、給藥途徑（口服途徑、腸外途徑、經皮症適應症、終端使用者（終端使用者（終端使用者）

受訪公司範例（總合42家公司）

• Abbott Laboratories
• Acadia Pharmaceuticals Inc.
• Alector, Inc.
• Anavex Life Sciences Corp.
• Annovis Bio, Inc.
• AstraZeneca plc
• Biogen Inc.
• Boston Scientific Corporation
• Ceregene, Inc.
• Coave Therapeutics
• Denali Therapeutics Inc.
• Integra LifeSciences Holdings Corp.
• Medtronic plc
• Merck & Co., Inc.
• NeuExcell Therapeutics
• Neurona Therapeutics, Inc.
• Novartis AG
• Pfizer Inc.
• Polyganics BV
• Teva Pharmaceutical Industries Ltd.

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地以及進出口（成品和OEM）預測公司競爭地位的變化。這種複雜且多方面的市場動態預計將以多種方式影響競爭對手，包括人為提高銷貨成本、降低盈利、重組供應鏈等微觀和宏觀市場動態。

全球產業分析師密切關注世界領先的首席經濟學家（14,949）、智庫（62）和貿易及產業協會（171）的專家意見，以評估生態系統的影響並應對新的市場現實。各主要國家的專家和經濟學家都在關注關稅及其對國家的影響。

全球產業分析師預計，這種動盪將在未來幾個月內平息，新的世界秩序將更加明確地建立。全球產業分析師正在即時追蹤這些發展。

2025年4月：談判階段

我們四月份的發布將涵蓋關稅對全球市場整體的影響，並為各地區的市場調整提供指導。我們的預測是基於歷史數據和不斷發展的市場影響因素。

2025年7月：最終關稅調整

免費更新 在各國宣布最終重置後，本公司的客戶將在 7 月收到免費更新。最終更新包含明確的關稅影響分析。

相互和雙邊貿易及關稅影響分析：

美國<>中國<>墨西哥<>加拿大<>歐盟<>日本<>印度<>其他176個國家

領先的產業經濟學家：全球產業分析師知識庫追蹤 14,949 位經濟學家，其中包括來自民族國家、智庫、貿易和產業協會、大型企業和領域專家的最具影響力的首席經濟學家，他們共用了全球經濟狀況這一前所未有的模式轉移的影響。我們的 16,491 多份報告中的大多數都遵循這個基於兩階段里程碑的發布計劃。

目錄

第1章調查方法

第2章執行摘要

• 市場概覽
• 主要企業
• 市場趨勢和促進因素
• 全球市場展望

第3章市場分析

• 美國
• 加拿大
• 日本
• 中國
• 歐洲
• 法國
• 德國
• 義大利
• 英國
• 西班牙
• 俄羅斯
• 其他歐洲國家
• 亞太地區
• 澳洲
• 印度
• 韓國
• 其他亞太地區
• 拉丁美洲
• 阿根廷
• 巴西
• 墨西哥
• 其他拉丁美洲
• 中東
• 伊朗
• 以色列
• 沙烏地阿拉伯
• 阿拉伯聯合大公國
• 其他中東地區
• 非洲

第4章 競賽

Global Neuroregeneration Therapy Market to Reach US$47.2 Billion by 2030

The global market for Neuroregeneration Therapy estimated at US$37.8 Billion in the year 2024, is expected to reach US$47.2 Billion by 2030, growing at a CAGR of 3.8% over the analysis period 2024-2030. N-methyl-D-aspartate Receptor Antagonists, one of the segments analyzed in the report, is expected to record a 4.0% CAGR and reach US$17.9 Billion by the end of the analysis period. Growth in the Cholinesterase Inhibitors segment is estimated at 2.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$10.3 Billion While China is Forecast to Grow at 7.0% CAGR

The Neuroregeneration Therapy market in the U.S. is estimated at US$10.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$9.5 Billion by the year 2030 trailing a CAGR of 7.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.5% and 2.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.2% CAGR.

Global Neuroregeneration Therapy Market - Key Trends & Drivers Summarized

Why Is Neuroregeneration Therapy Gaining Global Momentum in the Treatment of CNS and PNS Injuries?

Neuroregeneration therapy is emerging as a frontier area in neuroscience and regenerative medicine, offering hope for patients suffering from central and peripheral nervous system damage. Traditionally considered irreversible, neural injuries caused by trauma, stroke, neurodegenerative diseases, or demyelination are now being targeted with interventions that promote axonal regrowth, synaptic reformation, remyelination, and functional recovery. This paradigm shift from symptomatic management to actual nerve tissue repair is revolutionizing neurological rehabilitation and positioning neuroregeneration as a cornerstone of future neurotherapeutics.

The demand for neuroregeneration therapy is driven by the increasing global incidence of spinal cord injuries, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, and traumatic brain injuries. With an aging population and rising road traffic accidents and sports-related traumas, the number of individuals suffering from debilitating neurological impairments continues to rise. Traditional therapies offer limited recovery potential and focus largely on slowing disease progression. In contrast, neuroregeneration therapies aim to restore lost function, giving rise to a new generation of curative, rather than palliative, treatment strategies.

How Are Emerging Modalities Like Stem Cells, Growth Factors, and Gene Therapies Transforming Neuroregeneration?

The technological core of neuroregeneration therapy revolves around cutting-edge biologics and engineered cell systems. Stem cell therapy-particularly mesenchymal stem cells (MSCs), induced pluripotent stem cells (iPSCs), and neural progenitor cells-is one of the most advanced approaches under clinical development. These cells secrete neurotrophic factors, modulate inflammation, and differentiate into neuron-like cells that aid in repairing damaged neural tissue. Clinical trials are exploring their use in spinal cord injuries, stroke recovery, ALS, and multiple sclerosis with promising early results.

Growth factor therapies-including brain-derived neurotrophic factor (BDNF), glial cell line-derived neurotrophic factor (GDNF), and ciliary neurotrophic factor (CNTF)-are being delivered through viral vectors, biomaterials, or direct infusion to promote neuronal survival and plasticity. Gene therapies targeting neuroinflammation, myelin repair, or synaptic dysfunction are showing potential, especially in hereditary neurodegenerative diseases. Advances in biomaterial scaffolds, hydrogel matrices, and neural interfaces are also enabling localized, sustained delivery of these regenerative agents. These innovations are redefining therapeutic expectations, emphasizing neural restoration and circuit reintegration over mere symptom suppression.

Which Clinical Applications and Patient Populations Are Shaping the Neuroregeneration Market Landscape?

Neuroregeneration therapy is being investigated across a wide range of clinical applications, including spinal cord injuries, traumatic brain injuries (TBIs), peripheral nerve injuries, ischemic stroke, multiple sclerosis, and neurodegenerative diseases such as ALS and Parkinson’s. Patients with chronic neural damage-especially those with partial residual function or early-stage degeneration-are currently the best candidates for regenerative intervention. The pediatric neurology segment, particularly in cerebral palsy and congenital neural tube defects, is also a target for future therapeutic innovation.

Regions with high incidence of neurotrauma, stroke, and aging-related neurodegeneration-such as North America, Europe, and Asia-Pacific-are driving clinical trial activity and market demand. The U.S. leads in terms of regulatory progress and stem cell clinical infrastructure, while Japan and South Korea are advancing regenerative trials under favorable regulatory regimes. Emerging markets in Latin America and the Middle East are investing in rehabilitation infrastructure and international trial participation, enabling wider access to experimental regenerative therapies. Increasing patient advocacy and awareness of clinical trial participation are further broadening the market’s reach.

What Is Driving Long-Term Growth and Innovation in the Neuroregeneration Therapy Market?

The growth in the neuroregeneration therapy market is driven by the convergence of stem cell biology, biomaterials science, molecular neurobiology, and precision gene editing. The recognition of the nervous system’s plasticity and the ability to stimulate endogenous repair mechanisms is shifting the clinical approach to neural injuries. Regulatory frameworks for advanced therapy medicinal products (ATMPs) are being refined to accelerate the development and commercialization of regenerative neurotherapies. Public and private investment in neurorestorative research is expanding, with cross-disciplinary collaboration fueling innovation.

Clinical validation, scalable manufacturing, ethical sourcing, and long-term safety monitoring remain critical challenges. However, as data from early-phase trials mature, and as delivery technologies become more refined, a growing number of neuroregeneration products are expected to reach market approval. The increasing integration of digital neurorehabilitation tools, wearable neurostimulation devices, and remote patient monitoring systems will further enhance treatment adherence and outcome tracking. As neuroregeneration becomes a key pillar of neurotherapeutics, it will play a transformative role in improving functional recovery and quality of life for millions worldwide.

SCOPE OF STUDY:

The report analyzes the Neuroregeneration Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs, Other Drug Types); Indication Type (Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication, Other Indications); Administration Route (Oral Route, Parenteral Route, Transdermal Route); End-Use (Hospital Pharmacies End-Use, Retail Pharmacies End-Use, Online Pharmacies End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 42 Featured) -

• Abbott Laboratories
• Acadia Pharmaceuticals Inc.
• Alector, Inc.
• Anavex Life Sciences Corp.
• Annovis Bio, Inc.
• AstraZeneca plc
• Biogen Inc.
• Boston Scientific Corporation
• Ceregene, Inc.
• Coave Therapeutics
• Denali Therapeutics Inc.
• Integra LifeSciences Holdings Corp.
• Medtronic plc
• Merck & Co., Inc.
• NeuExcell Therapeutics
• Neurona Therapeutics, Inc.
• Novartis AG
• Pfizer Inc.
• Polyganics B.V.
• Teva Pharmaceutical Industries Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of Covid-19 and a Looming Global Recession
  • Neuroregeneration Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Growing Understanding of CNS Plasticity Mechanisms Spurs Innovation in Neuroregeneration Therapies
  • Increased Incidence of Spinal Cord Injury and Stroke Expands Addressable Market for Regenerative Interventions
  • Emergence of Stem Cell and iPSC-Based Approaches Propels Growth in Cell Therapy Pipelines
  • Rising Investment in Neurotrophic Factor Research Enhances Drug Discovery Potential
  • Availability of Gene Therapy Vectors Strengthens Business Case for Precision Regeneration
  • Advances in Bioactive Scaffolds and Hydrogels Accelerate Adoption of Tissue Engineering Solutions
  • Integration of Electrical Stimulation Techniques Drives Synaptic Recovery and Functional Restoration
  • Global Increase in Neurotrauma-Linked Disabilities Sustains Demand for Regenerative Solutions
  • Adoption of 3D Bioprinting for Neural Tissue Constructs Throws the Spotlight on Personalized Regeneration
  • Expansion of Academic-Industry Collaborations Spurs Translational Neuroregeneration Research
  • Improved Preclinical Models Enhance Efficacy Validation in Early-Stage Drug Development
  • Rising Regulatory Support for Regenerative Medicines Drives Clinical Trial Approvals
  • Integration of AI in Cell Therapy Manufacturing Optimizes Scalability and Quality Control
  • Growing Availability of Companion Diagnostics Enhances Therapy Precision and Targeting
  • Limited Efficacy of Current Neurorestorative Therapies Strengthens Demand for Breakthrough Solutions
  • Public-Private Investments in Brain Injury Recovery Programs Accelerate Product Commercialization
  • Development of Nanocarrier-Based Delivery Systems Supports Efficient Neurotrophic Transport
  • Growing Pipeline for ALS, MS, and Parkinson's Disease Drives Diversified Applications
  • Complexities in Long-Term Efficacy and Safety Tracking Pose Clinical Trial Design Challenges
  • Increased Reimbursement Coverage for Cell-Based Therapies Expands Patient Accessibility
  • Technological Advancements in Live Imaging and CNS Mapping Facilitate Outcome Monitoring
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Neuroregeneration Therapy Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Neuroregeneration Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Neuroregeneration Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for N-methyl-D-aspartate Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for N-methyl-D-aspartate Receptor Antagonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for N-methyl-D-aspartate Receptor Antagonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Cholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Cholinesterase Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Cholinesterase Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Dopamine Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Dopamine Agonists by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Dopamine Agonists by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Immunomodulatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Immunomodulatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Immunomodulatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Parenteral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Transdermal Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Transdermal Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Transdermal Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Hospital Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Hospital Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Hospital Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 32: World Recent Past, Current & Future Analysis for Retail Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 33: World Historic Review for Retail Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 34: World 15-Year Perspective for Retail Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 35: World Recent Past, Current & Future Analysis for Online Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 36: World Historic Review for Online Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 37: World 15-Year Perspective for Online Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 38: World Recent Past, Current & Future Analysis for Parkinson's Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 39: World Historic Review for Parkinson's Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 40: World 15-Year Perspective for Parkinson's Disease Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 41: World Recent Past, Current & Future Analysis for Alzheimer's Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 42: World Historic Review for Alzheimer's Disease Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 43: World 15-Year Perspective for Alzheimer's Disease Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 44: World Recent Past, Current & Future Analysis for Multiple Sclerosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 45: World Historic Review for Multiple Sclerosis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 46: World 15-Year Perspective for Multiple Sclerosis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 47: World Recent Past, Current & Future Analysis for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 48: World Historic Review for Other Indications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 49: World 15-Year Perspective for Other Indications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 50: USA Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: USA Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 52: USA 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 53: USA Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: USA Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 55: USA 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 56: USA Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: USA Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 58: USA 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 59: USA Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: USA Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 61: USA 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 62: Canada Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: Canada Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 64: Canada 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 65: Canada Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: Canada Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 67: Canada 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 68: Canada Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 69: Canada Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 70: Canada 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 71: Canada Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Canada Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 73: Canada 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• JAPAN
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 74: Japan Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Japan Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 76: Japan 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 77: Japan Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Japan Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 79: Japan 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 80: Japan Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: Japan Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 82: Japan 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 83: Japan Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: Japan Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 85: Japan 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• CHINA
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 86: China Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: China Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 88: China 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 89: China Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: China Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 91: China 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 92: China Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: China Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 94: China 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 95: China Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: China Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 97: China 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• EUROPE
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 98: Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 99: Europe Historic Review for Neuroregeneration Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 100: Europe 15-Year Perspective for Neuroregeneration Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 101: Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Europe Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 103: Europe 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 104: Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Europe Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 106: Europe 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 107: Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: Europe Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 109: Europe 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 110: Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: Europe Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 112: Europe 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• FRANCE
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 113: France Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: France Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 115: France 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 116: France Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: France Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 118: France 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 119: France Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: France Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 121: France 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 122: France Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: France Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 124: France 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• GERMANY
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 125: Germany Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Germany Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 127: Germany 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 128: Germany Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Germany Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 130: Germany 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 131: Germany Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Germany Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 133: Germany 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 134: Germany Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Germany Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 136: Germany 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 137: Italy Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Italy Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 139: Italy 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 140: Italy Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Italy Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 142: Italy 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 143: Italy Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 144: Italy Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 145: Italy 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 146: Italy Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Italy Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 148: Italy 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 149: UK Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: UK Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 151: UK 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 152: UK Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: UK Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 154: UK 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 155: UK Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: UK Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 157: UK 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 158: UK Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: UK Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 160: UK 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 161: Spain Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Spain Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 163: Spain 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 164: Spain Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: Spain Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 166: Spain 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 167: Spain Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: Spain Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 169: Spain 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 170: Spain Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: Spain Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 172: Spain 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 173: Russia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: Russia Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 175: Russia 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 176: Russia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: Russia Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 178: Russia 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 179: Russia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: Russia Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 181: Russia 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 182: Russia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Russia Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 184: Russia 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Europe Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Europe 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Europe Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Europe 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 191: Rest of Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 192: Rest of Europe Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 193: Rest of Europe 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 194: Rest of Europe Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Rest of Europe Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 196: Rest of Europe 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 198: Asia-Pacific Historic Review for Neuroregeneration Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 199: Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Asia-Pacific Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 202: Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Asia-Pacific Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 205: Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 206: Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Asia-Pacific Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 208: Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 209: Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Asia-Pacific Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 211: Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 212: Australia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Australia Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 214: Australia 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 215: Australia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Australia Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 217: Australia 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 218: Australia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Australia Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 220: Australia 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 221: Australia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Australia Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 223: Australia 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• INDIA
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 224: India Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: India Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 226: India 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 227: India Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: India Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 229: India 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 230: India Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: India Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 232: India 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 233: India Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: India Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 235: India 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 236: South Korea Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: South Korea Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 238: South Korea 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 239: South Korea Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 240: South Korea Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 241: South Korea 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 242: South Korea Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: South Korea Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 244: South Korea 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 245: South Korea Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: South Korea Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 247: South Korea 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Rest of Asia-Pacific Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 250: Rest of Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Rest of Asia-Pacific Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 253: Rest of Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 254: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Rest of Asia-Pacific Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 256: Rest of Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 257: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Rest of Asia-Pacific Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 259: Rest of Asia-Pacific 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 260: Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 261: Latin America Historic Review for Neuroregeneration Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 262: Latin America 15-Year Perspective for Neuroregeneration Therapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 263: Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Latin America Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 265: Latin America 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 266: Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Latin America Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 268: Latin America 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 269: Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Latin America Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 271: Latin America 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 272: Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Latin America Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 274: Latin America 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 275: Argentina Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Argentina Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 277: Argentina 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 278: Argentina Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: Argentina Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 280: Argentina 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 281: Argentina Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: Argentina Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 283: Argentina 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 284: Argentina Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: Argentina Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 286: Argentina 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 287: Brazil Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Brazil Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 289: Brazil 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 290: Brazil Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Brazil Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 292: Brazil 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 293: Brazil Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Brazil Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 295: Brazil 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 296: Brazil Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Brazil Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 298: Brazil 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 299: Mexico Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Mexico Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 301: Mexico 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 302: Mexico Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Mexico Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 304: Mexico 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 305: Mexico Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 306: Mexico Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 307: Mexico 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 308: Mexico Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 309: Mexico Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 310: Mexico 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 312: Rest of Latin America Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 313: Rest of Latin America 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 315: Rest of Latin America Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 316: Rest of Latin America 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 317: Rest of Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 318: Rest of Latin America Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 319: Rest of Latin America 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 320: Rest of Latin America Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 321: Rest of Latin America Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 322: Rest of Latin America 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 323: Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 324: Middle East Historic Review for Neuroregeneration Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 325: Middle East 15-Year Perspective for Neuroregeneration Therapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 326: Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 327: Middle East Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 328: Middle East 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 329: Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 330: Middle East Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 331: Middle East 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 332: Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 333: Middle East Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 334: Middle East 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 335: Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 336: Middle East Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 337: Middle East 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 338: Iran Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 339: Iran Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 340: Iran 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 341: Iran Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 342: Iran Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 343: Iran 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 344: Iran Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 345: Iran Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 346: Iran 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 347: Iran Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 348: Iran Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 349: Iran 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 350: Israel Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 351: Israel Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 352: Israel 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 353: Israel Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 354: Israel Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 355: Israel 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 356: Israel Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 357: Israel Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 358: Israel 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 359: Israel Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 360: Israel Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 361: Israel 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 363: Saudi Arabia Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 364: Saudi Arabia 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 366: Saudi Arabia Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 367: Saudi Arabia 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 368: Saudi Arabia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 369: Saudi Arabia Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 370: Saudi Arabia 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 371: Saudi Arabia Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 372: Saudi Arabia Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 373: Saudi Arabia 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 374: UAE Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 375: UAE Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 376: UAE 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 377: UAE Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 378: UAE Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 379: UAE 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 380: UAE Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 381: UAE Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 382: UAE 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 383: UAE Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 384: UAE Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 385: UAE 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 387: Rest of Middle East Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 388: Rest of Middle East 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 390: Rest of Middle East Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 391: Rest of Middle East 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 392: Rest of Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 393: Rest of Middle East Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 394: Rest of Middle East 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 395: Rest of Middle East Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 396: Rest of Middle East Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 397: Rest of Middle East 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030
• AFRICA
  • Neuroregeneration Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 398: Africa Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 399: Africa Historic Review for Neuroregeneration Therapy by Drug Type - N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 400: Africa 15-Year Perspective for Neuroregeneration Therapy by Drug Type - Percentage Breakdown of Value Sales for N-methyl-D-aspartate Receptor Antagonists, Cholinesterase Inhibitors, Dopamine Agonists, Immunomodulatory Drugs and Other Drug Types for the Years 2015, 2025 & 2030
  • TABLE 401: Africa Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 402: Africa Historic Review for Neuroregeneration Therapy by Administration Route - Oral Route, Parenteral Route and Transdermal Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 403: Africa 15-Year Perspective for Neuroregeneration Therapy by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Parenteral Route and Transdermal Route for the Years 2015, 2025 & 2030
  • TABLE 404: Africa Recent Past, Current & Future Analysis for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 405: Africa Historic Review for Neuroregeneration Therapy by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 406: Africa 15-Year Perspective for Neuroregeneration Therapy by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online Pharmacies End-Use for the Years 2015, 2025 & 2030
  • TABLE 407: Africa Recent Past, Current & Future Analysis for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 408: Africa Historic Review for Neuroregeneration Therapy by Indication Type - Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
  • TABLE 409: Africa 15-Year Perspective for Neuroregeneration Therapy by Indication Type - Percentage Breakdown of Value Sales for Parkinson's Disease Indication, Alzheimer's Disease Indication, Multiple Sclerosis Indication and Other Indications for the Years 2015, 2025 & 2030

IV. COMPETITION